Nuvation Bio (NUVB) CSO sells 100K shares at $7.09
Nuvation Bio (NUVB) reported that its CSO, Gary Hattersley, exercised options for 100,000 shares at $1.87 each and sold them at $7.0924 per share under a 10b5-1 plan. The sale generated approximately $709K in gross proceeds, with a pre-tax spread of $522K. Hattersley retains 400,000 stock options, vesting over time until 2034.
How this was made
The 30-second read
Why it matters
The transaction size is modest, so price impact is expected to be limited; investors may monitor future option exercises.
Market read
Primary disclosure of an insider sale; low immediate trading relevance but useful for monitoring insider sentiment.
What to watch
The insider retains 400,000 options that could be exercised later, providing upside potential if the stock rallies.
Background
Form 4 filing reveals an insider's execution of a pre‑planned 10b5‑1 trade, a routine disclosure for public companies.
Ticker impact
CSO Gary Hattersley exercised 100,000 options at $1.87 and sold the shares at $7.09 under a 10b5‑1 plan, disclosed in a Form 4 filing.
Limited short‑term pressure; price may dip slightly on volume but unlikely to move beyond a few cents.
Form 4 is primary source; the transaction size is small for a public company, so market reaction is expected to be muted.
Market effects
None; the trade is company‑specific and does not affect the broader biotech sector.
No regional impact; the filing is limited to NUVB shareholders.
Minimal; only relevant to investors tracking insider activity.
Counterpoint
The sale could be interpreted as a signal of upcoming negative news, prompting a short‑term sell.
Key entities
- Chief Scientific OfficerGary Hattersley
Insider who exercised and sold 100,000 shares.
- CompanyNuvation Bio Inc.
Biotech firm listed on NASDAQ under ticker NUVB.
